America Is Getting Older, and Healthy-Longevity Spending Is Reshaping Interest in NAD+ Therapy

By 2034, adults aged 65 and over are projected to outnumber children in the United States for the first time in the nation’s history. The U.S. Census Bureau’s revised national population projections put the crossover at 77.0 million older adults against 76.5 million children under 18. That single line in a demographic table carries enormous weight for the health economy: it signals a country whose median consumer is older, more health-aware and increasingly willing to spend money on the idea of ageing well rather than simply treating disease once it arrives.

That shift is already visible in consumer behaviour. Interest in healthy-longevity products and services, from sleep tracking to nutrition coaching to clinician-guided wellness protocols, has moved out of a niche and into the mainstream. NAD+ therapy, a category built around a coenzyme that sits at the centre of cellular energy metabolism, is one of the more visible examples of how that demand is being channelled into medically supervised offerings.

The demographic engine behind the longevity economy

The numbers behind the trend are structural rather than cyclical. According to the Census Bureau, every member of the baby boom generation will be older than 65 by 2030, at which point roughly one in five U.S. residents will be of retirement age. The bureau also projects the national median age to rise from 38 to 43 by 2060, and the ratio of working-age adults to each retirement-age person to fall from about 3.5 in 2020 to about 2.5 in 2060.

The pattern is global. McKinsey, citing World Health Organization estimates, notes that one in six people worldwide will be 60 or older by 2030. For healthcare systems, that means more people living longer with conditions that need ongoing management. For consumers, it means more years in which energy, recovery and cognitive sharpness feel like assets worth protecting.

Chronic disease sets the backdrop

The Centers for Disease Control and Prevention reports that three in four American adults have at least one chronic condition and more than half have two or more. Among adults aged 65 and older, roughly nine in ten live with at least one chronic condition. The CDC also states that 90 per cent of the nation’s $5.3 trillion in annual health care expenditures go to people with chronic and mental health conditions.

Those figures explain why “healthspan,” the number of years lived in good health, has become as important a talking point as lifespan. A system that spends most of its money on chronic disease creates a strong incentive, for individuals and payers alike, to look earlier and more proactively at how people age.

How healthy-longevity spending is growing

McKinsey’s research on the consumer wellness market sizes the global category at roughly $1.8 trillion and estimates the U.S. wellness market at about $480 billion, growing 5 to 10 per cent per year. Within that, healthy ageing has become one of the most dynamic segments. In McKinsey’s survey of consumers in China, the United Kingdom and the United States, more than 60 per cent said products or services for healthy ageing and longevity were “very” or “extremely” important to them. Roughly 70 per cent of U.S. and U.K. consumers reported buying more in this category over the past year than in prior years.

From supplements to supervised care

The first wave of longevity spending was largely retail: vitamins, powders and over-the-counter supplements bought without clinical input. The more recent wave looks different. Consumers who have grown comfortable with telehealth and direct-to-consumer pharmacy models increasingly expect a clinician to be involved, particularly when a product is prescribed, compounded or administered by injection.

That expectation matters for categories like NAD+, where interest is high but the science is still developing. A supervised model adds a layer of screening that retail channels do not: a licensed clinician reviews health history, considers contraindications and decides whether a prescription is appropriate at all.

Why NAD+ draws attention

Nicotinamide adenine dinucleotide is a coenzyme found in every living cell. It participates in hundreds of metabolic reactions, including the conversion of nutrients into usable cellular energy, and it serves as a substrate for enzyme families such as sirtuins and PARPs that are involved in DNA maintenance and cellular signalling. Laboratory research has documented that NAD+ levels tend to decline with age in a range of tissues, which is the main reason the molecule has become a focus of longevity research.

It is important to separate that research interest from conclusions about outcomes in people. Human studies of NAD+ and its precursors are still relatively small and short, and researchers continue to investigate questions about absorption, appropriate patient populations and long-term effects. Clinicians who prescribe NAD+ generally frame it as a wellness protocol considered on an individual basis, not as a treatment for a specific disease.

Who is driving demand?

Healthy-longevity spending is often associated with retirees, but the profile of interested consumers is broader. The CDC reports that more than 75 per cent of adults aged 35 to 64 already have at least one chronic condition, which places many mid-career professionals squarely in the population thinking about prevention. This group tends to be digitally fluent, time-constrained and accustomed to managing other parts of life through apps and subscriptions.

• Pre-retirees (50 to 64): often focused on maintaining energy and productivity through the final working decade.
• Active older adults (65 and over): interested in mobility, recovery and independence, and frequently managing multiple prescriptions already.
• Mid-career professionals (35 to 49): early adopters of wearables, sleep tracking and performance-oriented wellness.

Across all three groups, the common thread is a preference for convenience combined with clinical oversight. Few people want to schedule an in-person visit to discuss a wellness protocol, but many are uneasy buying an injectable product without a prescriber involved.

How it works in practice

Telehealth pharmacies have become one of the main routes through which consumers access clinician-guided longevity care. HealSend, a U.S. direct-to-consumer telehealth pharmacy verified by LegitScript, illustrates how the model is typically structured. Patients interested in NAD+ therapy begin with an online application, which the company describes as taking around 90 seconds, and are then connected with a licensed medical provider entirely online.

A clinician reviews the patient’s health history and goals and determines whether a prescription is appropriate. HealSend states that final treatment fit and pricing depend on that clinician review, and that there is no charge until a protocol is approved. When a patient is eligible, the prescription is shipped to their home, with ongoing support and check-ins afterwards.

HealSend lists NAD+ in more than one format, including a needle-free nasal spray and a subcutaneous injection that is self-administered at home. On the payment side, the company states that HSA and FSA funds are accepted and displays Klarna and Afterpay as options, and it describes plans as month-to-month. Service is limited to the U.S. states in which the company operates, and eligibility in every case depends on a licensed clinician’s assessment.

Friction points and what comes next

The longevity economy is growing quickly, but it faces several sources of friction that will shape how it matures over the next decade.

Evidence is still catching up with demand

Consumer enthusiasm for longevity products has outpaced the clinical literature. Much of the foundational work on NAD+ biology comes from cell and animal models, and translating those findings into people is slow, expensive work. The result is a gap that responsible operators fill with careful language and clinician judgment rather than promises. Expect the next few years to bring more human trials, more scrutiny of marketing claims and more emphasis on individualised assessment.

Regulation and verification

Because many longevity offerings involve compounded or prescription products, regulatory oversight is tightening. Third-party verification of online pharmacies, state-by-state licensing requirements for prescribers, and stricter advertising standards are all becoming part of the operating environment. For consumers, these signals offer a practical way to distinguish supervised care from unregulated retail products.

Paying for prevention

Traditional insurance is designed around diagnosis and treatment, which leaves most wellness and longevity spending as an out-of-pocket expense. That is one reason payment flexibility, including the use of tax-advantaged health accounts and instalment options, has become a competitive factor in the category. As the share of older Americans grows, pressure on payers to reconsider how prevention is financed is likely to grow with it.

The shrinking support ratio

The Census Bureau’s projection that the number of working-age adults per retiree will fall toward 2.5 by 2060 has implications well beyond pensions. Fewer caregivers per older adult means more value placed on staying independent for longer. That dynamic is likely to keep healthy ageing near the top of consumer priorities regardless of how any individual product category performs.

Conclusion

The ageing of the U.S. population is not a forecast so much as a fact already in motion. With baby boomers all crossing 65 by 2030 and older adults on track to outnumber children by 2034, demand for products and services that promise more healthy years is set to keep rising. Consumers are signalling, through their spending, that they want that care to be convenient, digital and supervised by clinicians.

The challenge for the longevity sector is to meet that demand without getting ahead of the science. Interest in molecules such as NAD+ reflects genuine and important research into how cells age, but the most durable part of the trend may be the model of care itself: individualised assessment, clear eligibility rules and an honest account of what is still unknown. A country growing older at this pace needs that kind of discipline as much as it needs innovation.

Pin It!